Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Lennox–Gastaut syndrome (LGS) is a severe epileptic and developmental encephalopathy that is associated with a high rate of morbidity and mortality. It is characterized by multiple seizure types, abnormal electroencephalographic features, and intellectual disability. Although intellectual disability and associated behavioral problems are characteristic of LGS, they are not necessarily present at its outset and are therefore not part of its diagnostic criteria. LGS is typically treated with a variety of pharmacological and non-pharmacological therapies, often in combination. Management and treatment decisions can be challenging, due to the multiple seizure types and comorbidities associated with the condition. A panel of five epileptologists met to discuss consensus recommendations for LGS management, based on the latest available evidence from literature review and clinical experience. Treatment algorithms were formulated. Current evidence favors the continued use of sodium valproate (VPA) as the first-line treatment for patients with newly diagnosed de novo LGS. If VPA is ineffective alone, evidence supports lamotrigine, or subsequently rufinamide, as adjunctive therapy. If seizure control remains inadequate, the choice of next adjunctive antiepileptic drug (AED) should be discussed with the patient/parent/caregiver/clinical team, as current evidence is limited. Non-pharmacological therapies, including resective surgery, the ketogenic diet, vagus nerve stimulation, and callosotomy, should be considered for use alongside AED therapy from the outset of treatment. For patients with LGS that has evolved from another type of epilepsy who are already being treated with an AED other than VPA, VPA therapy should be considered if not trialed previously. Thereafter, the approach for a de novo patient should be followed. Where possible, no more than two AEDs should be used concomitantly. Patients with established LGS should undergo review by a neurologist specialized in epilepsy on at least an annual basis, including a thorough reassessment of their diagnosis and treatment plan. Clinicians should always be vigilant to the possibility of treatable etiologies and alert to the possibility that a patient’s diagnosis may change, since the seizure types and electroencephalographic features that characterize LGS evolve over time. In all LGS patients, To date, available treatments are unlikely to lead to seizure remission in the majority of patients
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epileptic Syndromes in Infancy, Childhood and Adolescence
Rogers, J., Bureau, M., Dravet, C., Dreifuss, F. E., Perret, A., Wolf, P., & Armstrong, D. L. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199307000-00012 · Cited by 1,470
The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial
Neal, E. G., Chaffe, H., Schwartz, R. H., Lawson, M. S., Edwards, N., Fitzsimmons, G., Whitney, A., & Cross, J. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70092-9 · Cited by 1,224 · cited 1×
“The most common AEs were constipation, vomiting, hunger, and lack of energy (67).”
BackgroundSelf-citationCannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Morrow, J. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.074203 · Cited by 880
Side Effects of Corticosteroid Therapy
Buchman, A. L. (2001) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200110000-00006 · Cited by 745 · cited 1×
“In addition, prolonged use of steroids is associated with serious AEs, including growth suppression, hyperlipidemia, and osteoporosis (66).”
BackgroundThe longer term outcome of children born to mothers with epilepsy
Adab, N. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029132 · Cited by 580
Vagus-nerve stimulation for the treatment of epilepsy
Ben-Menachem, E. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00220-x · Cited by 560
Antiepileptic Drugs as a Cause of Worsening Seizures
Perucca, E., Gram, L., Avanzini, G., & Dulac, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01268.x · Cited by 543 · cited 1×
“, cognitive impairment, depression), and the choice of AED treatment must therefore take this possibility into consideration; for example, benzodiazepines used to treat sleep disorders may precipitate tonic seizures in LGS (106).”
BackgroundDrug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496 · cited 1×
“Some of these side effects may be attributable to comedication; cannabidiol is a potent inhibitor of enzymes in the cytochrome P450 pathway, and a definitive interaction has been reported with at least CLB (62).”
Background
Cited by
Knupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J. E., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0829 · Cited by 137
“At baseline, 233 of 263 patients (89%) were using 2 to 4 concomitant ASMs (median [range] number, 3 [1-5]).”
BackgroundHahn, C. D., Jiang, Y., Villanueva, V., Zolnowska, M., Arkilo, D., Hsiao, S., Asgharnejad, M., & Dlugos, D. (2022) · Epilepsia · doi:10.1111/epi.17367 · Cited by 81
The burden of illness in Lennox–Gastaut syndrome: a systematic literature review
Strzelczyk, A., Zuberi, S. M., Striano, P., Rosenow, F., & Schubert-Bast, S. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02626-4 · Cited by 68
“However, importantly, it has also become clear that there are caveats to these features which can make LGS challenging to define and diagnose [5].”
BackgroundSelf-citationKnupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., et al. (2023) · Epilepsia · doi:10.1111/epi.17431 · Cited by 55
Metadata
- Authors
- Cross, J. H., Auvin, S., Falip, M., Striano, P., & Arzimanoglou, A.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2017-09-29
- Volume
- 8
- Pages
- 505-505
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2760749448
- Cited by
- 205
- References
- 96
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.